{
    "nct_id": "NCT03561298",
    "official_title": "An Open-label, Fixed-Sequence Study in Healthy Male Subjects to Assess the Drug Interaction Potential of Multiple Doses of Zanubrutinib With a Drug \"Cocktail\" Representative for CYP3A4, CYP2C9, CYP2C19, P-gP and BCRP Substrates",
    "inclusion_criteria": "All Groups\n\n* Male subjects in good health as determined by past medical history, physical examination, vital signs, ECG and laboratory tests at screening.\n* Subjects must have a body mass index (BMI) between 18 and 32 kg/m2.\n* Male subjects must agree to a highly effective method of birth control from screening until at least 90 days after the last dose of study drug.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
    "exclusion_criteria": "* Subjects with a clinically relevant history or presence of any clinically significant disease.\n* History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed).\n* History of drug or alcohol abuse within 2 years prior to Check-In.\n* Alcohol consumption of >21 units per week.\n* A positive urine drug screen and/or positive alcohol breath test at Screening and/or Check-in.\n* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result and/or a positive human immunodeficiency virus (HIV) at screening.\n* Use of tobacco- or nicotine-containing products within 3 months prior to Check-In.\n* History of blood donation of 56 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.",
    "miscellaneous_criteria": ""
}